Dendritic cells (DCs) are antigen-presenting cells that play a key role in the induction of cytotoxic T-lymphocytes. Adjuvant immunotherapy with antigen-loaded DCs represents an attractive anticancer strategy for multiple myeloma (MM). Autologous DCs loaded with idiotypic protein or other myeloma-associated antigen have been used in several clinical trials. Preclinical and first clinical experience have provided valuable insights in the mechanisms of cellular immunity, but few, if any, patients with MM benefited from such vaccination. Taken together, the data suggest that antitumor T-cell responses fail in MM because of a deregulated cytokine network, downregulation of costimulatory surface receptor expression, and changes in T-cell repertoire, enabling tumor cells to escape immune effectors by preventing the antitumor immune response. We discuss current clinical protocols for DC-based immunotherapy in MM and review some strategies that may increase the efficacy of DC vaccines.

Department of Internal Medicine Hematooncology Masaryk University Hospital Jihlavska 20 63900 Brno Czech Republic

Med Oncol. 2002;19(4):195-6. doi: 10.1385/MO:19:4:195. PubMed

See more in PubMed

Biol Blood Marrow Transplant. 2000;6(6):621-7 PubMed

Blood Rev. 1999 Sep;13(3):151-62 PubMed

Leuk Lymphoma. 1999 Jan;32(3-4):223-36 PubMed

Immunol Cell Biol. 1999 Oct;77(5):451-9 PubMed

Blood. 1999 Apr 1;93(7):2411-9 PubMed

J Exp Med. 1996 Aug 1;184(2):695-706 PubMed

Clin Exp Immunol. 2001 Aug;125(2):190-7 PubMed

N Engl J Med. 1992 Oct 22;327(17):1209-15 PubMed

Eur J Immunol. 1997 Feb;27(2):431-41 PubMed

Exp Hematol. 2001 Nov;29(11):1247-55 PubMed

Vox Sang. 2001 Feb;80(2):81-9 PubMed

Nat Med. 1996 Jan;2(1):52-8 PubMed

J Exp Med. 1995 Jul 1;182(1):255-60 PubMed

Semin Oncol. 2000 Oct;27(5):598-613 PubMed

Cancer Res. 1995 Mar 1;55(5):1099-104 PubMed

Br J Haematol. 2002 May;117(2):297-305 PubMed

Clin Cancer Res. 1998 Apr;4(4):957-62 PubMed

Blood. 1999 Mar 1;93(5):1487-95 PubMed

Immunology. 1994 Jul;82(3):487-93 PubMed

J Immunol. 2001 Mar 15;166(6):4254-9 PubMed

Blood. 2001 Mar 15;97(6):1750-5 PubMed

Cancer Res. 2001 May 1;61(9):3725-34 PubMed

Blood. 1996 Jun 1;87(11):4520-30 PubMed

Hematology. 2000;4(6):471-477 PubMed

Blood. 1997 Nov 1;90(9):3245-87 PubMed

Med Oncol. 2000 Feb;17(1):2-15 PubMed

Immunology. 1997 Aug;91(4):553-9 PubMed

Exp Hematol. 1996 Jul;24(8):859-62 PubMed

Br J Haematol. 1999 Dec;107(3):648-55 PubMed

Blood. 2001 Nov 15;98(10):2992-8 PubMed

Blood. 1997 Nov 15;90(10):4206-11 PubMed

Haematologica. 2001 Oct;86(10):1029-37 PubMed

Nature. 1998 Mar 19;392(6673):245-52 PubMed

Semin Hematol. 1995 Jan;32(1):31-44 PubMed

Blood. 1998 Apr 1;91(7):2459-66 PubMed

Int J Cancer. 1999 Oct 8;83(2):215-22 PubMed

J Immunol Methods. 1996 Sep 27;196(2):121-35 PubMed

Blood. 1999 Jul 15;94(2):673-83 PubMed

Blood. 2000 Nov 1;96(9):3102-8 PubMed

Nat Med. 2001 Oct;7(10):1159-62 PubMed

J Immunol Methods. 1996 Sep 27;196(2):137-51 PubMed

J Immunol. 2000 May 1;164(9):4797-803 PubMed

Br J Haematol. 2000 Mar;108(4):805-16 PubMed

Br J Haematol. 2001 Jun;113(4):1051-9 PubMed

J Exp Med. 1995 Aug 1;182(2):389-400 PubMed

Nat Med. 1998 Mar;4(3):328-32 PubMed

Blood. 2002 May 1;99(9):3280-5 PubMed

Isolation and expansion of allogeneic myeloma-specific interferon-gamma producing T cells for adoptive immunotherapy